Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer

Oncogene

Volumn 31, Issue 35, 2012, Pages 3939-3948

  Liu, W ^a   Lindberg, J ^b   Sui, G ^a   Luo, J ^c   Egevad, L ^d   Li, T ^a   Xie, C ^a   Wan, M ^a   Kim, S T ^a   Wang, Z ^a   Turner, A R ^a   Zhang, Z ^a   Feng, J ^a   Yan, Y ^e   Sun, J ^a   Bova, G S ^c   Ewing, C M ^c   Yan, G ^c   Gielzak, M ^c   Cramer, S D ^a   Vessella, R L ^f   Zheng, S L ^a   Gronberg H ^b   Isaacs, W B ^c   Xu, J ^a,e   more..

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e VAN ANDEL RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

CHD1; homozygous deletion; prostate cancer

Indexed keywords

ANIMAL CELL; ARTICLE; CHD 1 GENE; CHROMOSOME DELETION; CONTROLLED STUDY; EXON; GENE; GENE DELETION; GENE FUNCTION; GENE IDENTIFICATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT;

ANIMALS; CELL LINE; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA HELICASES; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE DELETION; HEK293 CELLS; HOMOZYGOTE; HUMANS; MALE; MICE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

EID: 84865639773     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.554     Document Type: Article

References (41)

1. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM et al. (2011). Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469: 356-361.
2. Avvakumov N, Nourani A, Cote J. (2011). Histone chaperones: modulators of chromatin marks. Mol Cell 41: 502-514.
3. Barclay WW, Axanova LS, Chen W, Romero L, Maund SL, Soker S et al. (2008). Characterization of adult prostatic progenitor/stem cells exhibiting self-renewal and multilineage differentiation. Stem Cells 26: 600-610.
4. Barclay WW, Cramer SD. (2005). Culture of mouse prostatic epithelial cells from genetically engineered mice. Prostate 63: 291-298.
5. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY et al. (2011). The genomic complexity of primary human prostate cancer. Nature 470: 214-220.
6. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D et al. (2007). Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 104: 20007-20012.
7. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J et al. (2010). The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905.
8. Bettermann K, Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F et al. (2010). TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell 17: 481-496.
9. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews JM et al. (2010). Signatures of mutation and selection in the cancer genome. Nature 463: 893-898.
10. Cao P, Deng Z, Wan M, Huang W, Cramer SD, Xu J et al. (2010). MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer 9: 108.
11. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A et al. (2009). Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41: 619-624.
12. Cengiz B, Gunduz M, Nagatsuka H, Beder L, Gunduz E, Tamamura R et al. (2007). Fine deletion mapping of chromosome 2q21-37 shows three preferentially deleted regions in oral cancer. Oral Oncol 43: 241-247.
13. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A et al. (2010). Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360-363.
14. Deng Z, Wan M, Cao P, Rao A, Cramer SD, Sui G. (2009). Yin Yang 1 regulates the transcriptional activity of androgen receptor. Oncogene 28: 3746-3757.
15. Deng Z, Wan M, Sui G. (2007). PIASy-mediated sumoylation of Yin Yang 1 depends on their interaction but not the RING finger. Mol Cell Biol 27: 3780-3792.
16. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al. (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
17. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J et al. (2011). SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 466: 869-873.
18. Gaspar-Maia A, Alajem A, Polesso F, Sridharan R, Mason MJ, Heidersbach A et al. (2009). Chd1 regulates open chromatin and pluripotency of embryonic stem cells. Nature 460: 863-868.
19. Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R et al. (2010). Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228-231.
20. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM et al. (2010). Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466: 869-873.
21. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH et al. (2009). Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41: 524-526.
22. Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H et al. (2010). A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer 49: 342-352.
23. Konev AY, Tribus M, Park SY, Podhraski V, Lim CY, Emelyanov AV et al. (2007). CHD1 motor protein is required for deposition of histone variant H3.3 into chromatin in vivo. Science 317: 1087-1090.
24. Liu W, Chang BL, Cramer S, Koty PP, Li T, Sun J et al. (2007). Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. Clin Cancer Res 13: 5028-5033.
25. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G et al. (2009). Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 15: 559-565.
26. Lu YJ, Wu CS, Li HP, Liu HP, Lu CY, Leu YW et al. (2010). Aberrant methylation impairs low density lipoprotein receptor-related protein 1B tumor suppressor function in gastric cancer. Genes Chromosomes Cancer 49: 412-424.
27. McDaniel IE, Lee JM, Berger MS, Hanagami CK, Armstrong JA. (2008). Investigations of CHD1 function in transcription and development of Drosophila melanogaster. Genetics 178: 583-587.
28. Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, Yokota J et al. (2008). Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat 29: 617-622.
29. Nancarrow DJ, Handoko HY, Smithers BM, Gotley DC, Drew PA, Watson DI et al. (2008). Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays. Cancer Res 68: 4163-4172.
30. Rahrmann EP, Collier LS, Knutson TP, Doyal ME, Kuslak SL, Green LE et al. (2009). Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen. Cancer Res 69: 4388-4397.
31. Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom-Sternberg S et al. (2011). Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res 21: 47-55.
32. Siegel R, Ward E, Brawley O, Jemal A. (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
33. Sims 3rd RJ, Millhouse S, Chen CF, Lewis BA, Erdjument-Bromage H, Tempst P et al. (2007). Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing. Mol Cell 28: 665-676.
34. Sims 3rd RJ, Reinberg D. (2009). Stem cells: escaping fates with open states. Nature 460: 802-803.
35. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ et al. (2011). Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144: 27-40.
36. Stokes DG, Perry RP. (1995). DNA-binding and chromatin localization properties of CHD1. Mol Cell Biol 15: 2745-2753.
37. Sui G, Shi Y. (2005). Gene silencing by a DNA vector-based RNAi technology. Methods Mol Biol 309: 205-218.
38. Sui G, Soohoo C, Affar el B, Gay F, Shi Y, Forrester WC et al. (2002). A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 99: 5515-5520.
39. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
40. Weissman B, Knudsen KE. (2009). Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res 69: 8223-8230 Review.
41. Yin D, Ogawa S, Kawamata N, Tunici P, Finocchiaro G, Eoli M et al. (2009). High-resolution genomic copy number profiling of glioblas-toma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res 7: 665-677.